
Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.
Nicholas James Hornstein, MD, PhD, discusses the past, present, and future of colorectal cancer management.
Nicholas James Hornstein, MD, PhD, discusses the past, present, and future of colorectal cancer management.

